Search Results - "Betge, Johannes"

CRISPR/Cas9 for cancer research and therapy by Zhan, Tianzuo, Rindtorff, Niklas, Betge, Johannes, Ebert, Matthias P., Boutros, Michael

“…CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system,…”
Get full text

MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer by Zhan, Tianzuo, Ambrosi, Giulia, Wandmacher, Anna Maxi, Rauscher, Benedikt, Betge, Johannes, Rindtorff, Niklas, Häussler, Ragna S., Hinsenkamp, Isabel, Bamberg, Leonhard, Hessling, Bernd, Müller-Decker, Karin, Erdmann, Gerrit, Burgermeister, Elke, Ebert, Matthias P., Boutros, Michael

“…In colorectal cancer (CRC), aberrant Wnt signalling is essential for tumorigenesis and maintenance of cancer stem cells. However, how other oncogenic pathways…”
Get full text

Precision medicine for metastatic colorectal cancer in clinical practice by Riedesser, Julian E., Ebert, Matthias P., Betge, Johannes

“…Globally, metastatic colorectal cancer is one of the leading causes for cancer-related death. Treatment limited to conventional chemotherapeutics extended life…”
Get full text

MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance by Betge, Johannes, Schneider, Nora I., Harbaum, Lars, Pollheimer, Marion J., Lindtner, Richard A., Kornprat, Peter, Ebert, Matthias P., Langner, Cord

“…Mucin glycoprotein expression can be altered during the carcinogenic process. The impact on the prognosis of patients with colorectal cancer (CRC) is…”
Get full text

Prognostic Cancer Gene Expression Signatures: Current Status and Challenges by Qian, Yuquan, Daza, Jimmy, Itzel, Timo, Betge, Johannes, Zhan, Tianzuo, Marmé, Frederik, Teufel, Andreas

“…Current staging systems of cancer are mainly based on the anatomical extent of disease. They need refinement by biological parameters to improve stratification…”
Get full text

The drug-induced phenotypic landscape of colorectal cancer organoids by Betge, Johannes, Rindtorff, Niklas, Sauer, Jan, Rauscher, Benedikt, Dingert, Clara, Gaitantzi, Haristi, Herweck, Frank, Srour-Mhanna, Kauthar, Miersch, Thilo, Valentini, Erica, Boonekamp, Kim E., Hauber, Veronika, Gutting, Tobias, Frank, Larissa, Belle, Sebastian, Gaiser, Timo, Buchholz, Inga, Jesenofsky, Ralf, Härtel, Nicolai, Zhan, Tianzuo, Fischer, Bernd, Breitkopf-Heinlein, Katja, Burgermeister, Elke, Ebert, Matthias P., Boutros, Michael

“…Patient-derived organoids resemble the biology of tissues and tumors, enabling ex vivo modeling of human diseases. They have heterogeneous morphologies with…”
Get full text

Unveiling the culprit: the fusobacterium lineage that populates colorectal cancer by Betge, Johannes, Ebert, Matthias P.

Get full text

Patient-Derived Organoids of Cholangiocarcinoma by Maier, Christopher Fabian, Zhu, Lei, Nanduri, Lahiri Kanth, Kühn, Daniel, Kochall, Susan, Thepkaysone, May-Linn, William, Doreen, Grützmann, Konrad, Klink, Barbara, Betge, Johannes, Weitz, Jürgen, Rahbari, Nuh N., Reißfelder, Christoph, Schölch, Sebastian

“…Cholangiocarcinoma (CC) is an aggressive malignancy with an inferior prognosis due to limited systemic treatment options. As preclinical models such as CC cell…”
Get full text

Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study by Dreikhausen, Lena, Klupsch, Anna, Wiest, Isabella, Xiao, Qiyun, Schulte, Nadine, Betge, Johannes, Boch, Tobias, Brochhausen, Christoph, Gaiser, Timo, Hofheinz, Ralf-Dieter, Ebert, Matthias, Zhan, Tianzuo

“…Panel gene sequencing is an established diagnostic tool for precision oncology of solid tumors, but its utility for the treatment of cancers of the digestive…”
Get full text

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) by Meindl-Beinker, Nadja M, Betge, Johannes, Gutting, Tobias, Burgermeister, Elke, Belle, Sebastian, Zhan, Tianzuo, Schulte, Nadine, Maenz, Martin, Ebert, Matthias P, Haertel, Nicolai

“…Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data…”
Get full text

A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax) by Betge, Johannes, Chi-Kern, Jing, Schulte, Nadine, Belle, Sebastian, Gutting, Tobias, Burgermeister, Elke, Jesenofsky, Ralf, Maenz, Martin, Wedding, Ulrich, Ebert, Matthias P, Haertel, Nicolai

“…In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line…”
Get full text

PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells by Gutting, Tobias, Hauber, Veronika, Pahl, Jens, Klapproth, Kay, Wu, Wenyue, Dobrota, Ioana, Herweck, Frank, Reichling, Juliane, Helm, Laura, Schroeder, Torsten, Li, Beifang, Weidner, Philip, Zhan, Tianzuo, Eckardt, Maximilian, Betge, Johannes, Belle, Sebastian, Sticht, Carsten, Gaiser, Timo, Boutros, Michael, Ebert, Matthias P.A., Cerwenka, Adelheid, Burgermeister, Elke

“…Only a small subset of colorectal cancer (CRC) patients benefits from immunotherapies, comprising blocking antibodies (Abs) against checkpoint receptor…”
Get full text

Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples by Betge, Johannes, Kerr, Grainne, Miersch, Thilo, Leible, Svenja, Erdmann, Gerrit, Galata, Christian L, Zhan, Tianzuo, Gaiser, Timo, Post, Stefan, Ebert, Matthias P, Horisberger, Karoline, Boutros, Michael

“…Next generation sequencing (NGS) is an emerging technology becoming relevant for genotyping of clinical samples. Here, we assessed the stability of amplicon…”
Get full text

Detection of mutational patterns in cell‐free DNA of colorectal cancer by custom amplicon sequencing by Herrmann, Simon, Zhan, Tianzuo, Betge, Johannes, Rauscher, Benedikt, Belle, Sebastian, Gutting, Tobias, Schulte, Nadine, Jesenofsky, Ralf, Härtel, Nicolai, Gaiser, Timo, Hofheinz, Ralf‐Dieter, Ebert, Matthias P., Boutros, Michael

“…Monitoring the mutational patterns of solid tumors during cancer therapy is a major challenge in oncology. Analysis of mutations in cell‐free (cf) DNA offers a…”
Get full text

Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer by Barat, Ana, Smeets, Dominiek, Moran, Bruce, Zhang, Wu, Cao, Shu, Das, Sudipto, Klinger, Rut, Betge, Johannes, Murphy, Verena, Bacon, Orna, Kay, Elaine W., Van Grieken, Nicole C. T., Verheul, Henk M. W., Gaiser, Timo, Schulte, Nadine, Ebert, Matthias P., Fender, Bozena, Hennessy, Bryan T., McNamara, Deborah A., O’Connor, Darran, Gallagher, William M., Cremolini, Chiara, Loupakis, Fotios, Parikh, Aparna, Mancao, Christoph, Ylstra, Bauke, Lambrechts, Diether, Lenz, Heinz-Josef, Byrne, Annette T., Prehn, Jochen H. M.

“…Chemotherapy combined with the angiogenesis inhibitor bevacizumab (BVZ) is approved as a first-line treatment in metastatic colorectal cancer (mCRC). Limited…”
Get full text

Cancer-Associated Mutations in Normal Colorectal Mucosa Adjacent to Sporadic Neoplasia by Zhan, Tianzuo, Belle, Sebastian, Valentini, Erica, Herrmann, Simon, Miersch, Thilo, Li, Moying, Gaiser, Timo, Boutros, Michael, Ebert, Matthias P., Betge, Johannes

“…Colorectal cancer arises in a multistep process of carcinogenesis from normal mucosa. The earliest precursor might be a morphologically inconspicuous…”
Get full text

Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial by Ebert, Matthias P, Meindl-Beinker, Nadja M, Gutting, Tobias, Maenz, Martin, Betge, Johannes, Schulte, Nadine, Zhan, Tianzuo, Weidner, Philip, Burgermeister, Elke, Hofheinz, Ralf, Vogel, Arndt, Angermeier, Stefan, Bolling, Claus, de Wit, Maike, Jakobs, Ralf, Karthaus, Meinolf, Stocker, Gertraud, Thuss-Patience, Peter, Leidig, Tobias, Gaiser, Timo, Kather, Jakob N, Haertel, Nicolai

“…The overall survival of patients with advanced and refractory oesophageal squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1…”
Get full text

Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma by Weidner, Philip, Söhn, Michaela, Schroeder, Torsten, Helm, Laura, Hauber, Veronika, Gutting, Tobias, Betge, Johannes, Röcken, Christoph, Rohrbacher, Florian N., Pattabiraman, Vijaya R., Bode, Jeffrey W., Seger, Rony, Saar, Daniel, Nunes-Alves, Ariane, Wade, Rebecca C., Ebert, Matthias P. A., Burgermeister, Elke

“…Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor drugable by agonists approved for treatment of type 2 diabetes, but also…”
Get full text

Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients by Venken, Tom, Miller, Ian S., Arijs, Ingrid, Thomas, Valentina, Barat, Ana, Betge, Johannes, Zhan, Tianzuo, Gaiser, Timo, Ebert, Matthias P., O’Farrell, Alice C., Prehn, Jochen, Klinger, Rut, O’Connor, Darran P., Moulton, Brian, Murphy, Verena, Serna, Garazi, Nuciforo, Paolo G., McDermott, Ray, Bird, Brian, Leonard, Gregory, Grogan, Liam, Horgan, Anne, Schulte, Nadine, Moehler, Markus, Lambrechts, Diether, Byrne, Annette T.

“…To predict outcome to combination bevacizumab (BVZ) therapy, we employed cell-free DNA (cfDNA) to determine chromosomal instability (CIN), nucleosome…”
Get full text

Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer by Betge, Johannes, Kornprat, Peter, Pollheimer, Marion J., Lindtner, Richard A., Schlemmer, Andrea, Rehak, Peter, Vieth, Michael, Langner, Cord

Get full text